Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 3/20 | 0.34 |
| ▸ | TERT | O14746 | 3/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | F7 | P08709 | 2/20 | 0.31 |
| ▸ | F3 | P13726 | 2/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191498 | 1.00 | HIF1A (0.53) | HIF1AFAAHTRPV1TSHRMAPT | |
| SCHEMBL9126791 | 0.95 | TRPV1 (0.46) | HIF1AFAAHTRPV1TSHRMAPT | |
| SCHEMBL4326660 | 0.95 | FAAH (0.58) | HIF1AFAAHTRPV1TSHRMAPT | |
| SCHEMBL87783 | 0.95 | TRPV1 (0.46) | HIF1AFAAHTRPV1TSHRMAPT | |
| SCHEMBL9126784 | 0.95 | TRPV1 (0.46) | HIF1AFAAHTRPV1TSHRMAPT | |
| SCHEMBL18076299 | 0.95 | FAAH (0.58) | HIF1AFAAHTRPV1TSHRMAPT | |
| SCHEMBL18076300 | 0.95 | FAAH (0.58) | HIF1AFAAHTRPV1TSHRMAPT | |
| SCHEMBL2163219 | 0.95 | — | — | |
| SCHEMBL15865684 | 0.95 | — | — | |
| SCHEMBL4081590 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234253-B2 | Silicone compounds with a substituted amine group and a benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2025-02-25 | — | — | US | claimed |
| US-20250051370-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2025-02-13 | — | — | US | claimed |
| US-20220064191-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2022-03-03 | — | — | US | claimed |
| US-20080032913-A1 | Masking of mineral oil odor and fragrancing of mineral oils | SYMRISE GMBH & CO. KG (DE) | 2008-02-07 | — | — | US | claimed |
| EP-1884555-A2 | Masking mineral oil smell and scenting of mineral oils | Symrise GmbH & Co. KG (DE) | 2008-02-06 | — | — | EP | claimed |
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | PROCTER & GAMBLE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-30 | — | — | US | disclosed |
| US-12234253-B2 | Silicone compounds with a substituted amine group and a benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250051370-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2025-02-13 | — | — | US | disclosed |
| US-12037320-B2 | Pro-benefit-agent compounds with heterocyclic moieties | THE PROCTER & GAMBLE COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| US-20230220304-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID DIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| US-20230002330-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2023-01-05 | — | — | US | disclosed |
| US-20220403297-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH CARBON/NITROGEN BONDS | THE PROCTER & GAMBLE COMPANY | 2022-12-22 | — | — | US | disclosed |
| US-20220177813-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2022-06-09 | — | — | US | disclosed |
| US-20220064191-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2022-03-03 | — | — | US | disclosed |
| WO-2020142444-A1 | BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COMPOSITIONS COMPRISING SAME | DOW SILICONES CORPORATION (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051370-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | HIF1A 2770/4885FAAH 3791/4885TRPV1 3889/4885 |
| US-12037320-B2 | Pro-benefit-agent compounds with heterocyclic moieties | PLG, PAM, PREP | HIF1A 110/4885FAAH 78/4885TRPV1 1221/4885 |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | HGFAC, PROKR1, FABP2 | HIF1A 175/4885FAAH 36/4885TRPV1 1479/4885 |
| US-12234253-B2 | Silicone compounds with a substituted amine group and a benefit agent moiety | SMS, SRM, AAAS | HIF1A 3059/4885FAAH 2275/4885TRPV1 4223/4885 |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | ARGLU1, DAO, PNISR | HIF1A 2449/4885FAAH 1503/4885TRPV1 1763/4885 |
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | F2, C9, S100A8 | HIF1A 493/4885FAAH 598/4885TRPV1 1087/4885 |
| US-20230002330-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | PLG, PAM, PREP | HIF1A 110/4885FAAH 78/4885TRPV1 1221/4885 |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | BCAT2, MTR, ASNS | HIF1A 2167/4885FAAH 3346/4885TRPV1 2564/4885 |
| US-20220064191-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | HIF1A 2770/4885FAAH 3791/4885TRPV1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.